See where demand, money, & tech are moving in aesthetics.

Aesthetics is not one market — it is 50 state markets stacked on top of each other, and the price spread for the same Botox syringe ($252 in Wyoming, $703 in South Carolina) is wider than the spread between major European capitals.

Search intent leads procedure volume by ~6 months — and the highest-value queries aren't 'best medspa' but 'what would this look like on me'. The clinic that answers that on its own site captures the bookings everyone else loses to Google Images.

Injectables print 42% of revenue at the highest margins and the highest visit frequency — they are the only category that is simultaneously high-ticket, high-margin, and high-repeat. Every other service line is a cross-sell off injectables, not the other way around.

The next inflection is not retatrutide — it is the regulatory tightening on compounded GLP-1s that forces clinics to choose between branded supply economics and exiting the category. The clinics that adapt their wellness funnel for branded-only will pull share from the compounded operators within 18 months.

The funnel inflection has already happened: clinics using AI before/after preview tools convert visitors at 2.5× the rate of clinics that don't. The market hasn't recognized this yet because the early adopters won't show competitors their attribution data. In 12 months it will be table stakes.